Discordance Between HbA1c and Glucose Management Indicator in People With Type 2 Diabetes Treated With SGLT2 Inhibitors

Puntos clave

• This research examines whether SGLT2 inhibitors alter the interpretation of glycemic control metrics in individuals with type 2 diabetes.
• Analyzed the impact of SGLT2 inhibitors on HbA1c and glucose management indicators (HGI)
• Evaluated the role of patient-specific factors such as hematologic and renal conditions
• Emphasized the importance of continuous glucose monitoring (CGM) metrics and alternative biomarkers for assessment.
• SGLT2 inhibitors increase HGI levels while reducing GA/HbA1c
• Alterations in glycemic markers occur independently of hematologic and renal factors
• Individualized assessments of glycemic control are necessary to truly understand patient health outcomes.